false
0001583771
0001583771
2026-03-16
2026-03-16
0001583771
dei:FormerAddressMember
2026-03-16
2026-03-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 16, 2026
Hepion
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-36856 |
|
46-2783806 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(IRS
Identification No.) |
34
Shrewsbury Ave., Suite 1D
Red
Bank, NJ 07701
(Address
of principal executive offices)
(732)
902-4000
(Registrant’s
telephone number, including area code)
55
Madison Ave., Suite 400-PMB# 4362
Morristown,
NJ 07960
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class: |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered: |
| Common
Stock, par value $0.0001 per share |
|
HEPA |
|
OTC
QB |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure
of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
On
March 16, 2026, Dr. Kaouthar Lbiati, the Chief Executive Officer of Hepion Pharmaceuticals, Inc. (the “Company”) informed
the Board of Directors (the “Board”) of the Company that she was resigning as Chief Executive Officer for personal reasons,
effective immediately.
On
March 16, 2026, the Board approved the appointment of Gary Stetz as interim Chief Executive Officer of the Company and director and appointed
Vincent LoPriore as Executive Chairman, Sireesh Appajosyula as director and Chase LoPriore as director.
There
are no arrangements or understandings between Messrs. Stetz, V. LoPriore, Appajosyula and C. LoPriore and any other person pursuant to
which such person was selected as an officer or director of the Company, as the case may be, and there is no family relationship between
any of Mr. Stetz, Mr. V. LoPriore, Mr. Appajosyula and Mr. C. LoPriore and any of the Company’s other directors or executive officers.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date: March 18, 2026 |
Hepion Pharmaceuticals,
Inc. |
| |
|
|
| |
By: |
/s/
Gary Stetz |
| |
|
Gary Stetz |
| |
|
Interim Chief Executive Officer |
